Michael J. Farrell Sells 5,675 Shares of ResMed Inc. (NYSE:RMD) Stock

ResMed Inc. (NYSE:RMD – Get Rating) CEO Michael J. Farrell sold 5,675 shares of the company’s stock in a transaction on Tuesday, January 17th. The stock was sold at an average price of $224.36, for a total value of $1,273,243.00. Following the sale, the chief executive officer now owns 436,900 shares of the company’s stock, valued at $98,022,884. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

ResMed Stock Performance

NYSE:RMD opened at $229.30 on Friday. The company has a debt-to-equity ratio of 0.23, a current ratio of 2.94 and a quick ratio of 1.69. The firm has a 50-day moving average of $218.12 and a two-hundred day moving average of $222.72. The stock has a market cap of $33.59 billion, a P/E ratio of 42.86, a PEG ratio of 1.41 and a beta of 0.50. ResMed Inc. has a 1-year low of $189.40 and a 1-year high of $262.38.

ResMed (NYSE:RMD – Get Rating) last issued its earnings results on Thursday, October 27th. The medical equipment provider reported $1.51 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.51. The business had revenue of $950.30 million for the quarter, compared to analyst estimates of $946.07 million. ResMed had a net margin of 21.70% and a return on equity of 25.75%. The company’s revenue for the quarter was up 5.1% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.51 EPS. On average, research analysts expect that ResMed Inc. will post 6.45 earnings per share for the current fiscal year.

ResMed Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Thursday, December 15th. Stockholders of record on Thursday, November 10th were paid a $0.44 dividend. The ex-dividend date was Wednesday, November 9th. This represents a $1.76 dividend on an annualized basis and a dividend yield of 0.77%. ResMed’s dividend payout ratio (DPR) is presently 32.90%.

Wall Street Analyst Weigh In

RMD has been the subject of a number of research reports. JPMorgan Chase & Co. raised shares of ResMed from a “neutral” rating to an “overweight” rating and set a $245.00 price target for the company in a research report on Tuesday. Bank of America raised shares of ResMed from a “neutral” rating to a “buy” rating and upped their price target for the stock from $245.00 to $260.00 in a research report on Thursday, October 20th. Jefferies Financial Group initiated coverage on shares of ResMed in a research report on Wednesday, October 12th. They set a “hold” rating and a $245.00 price target for the company. Citigroup raised shares of ResMed from a “neutral” rating to a “buy” rating in a research report on Wednesday. Finally, KeyCorp upped their price target on shares of ResMed from $276.00 to $280.00 and gave the stock an “overweight” rating in a research report on Friday, October 28th. Three investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, ResMed currently has an average rating of “Moderate Buy” and a consensus target price of $263.43.

Institutional Investors Weigh In On ResMed

A number of institutional investors have recently modified their holdings of RMD. Kayne Anderson Rudnick Investment Management LLC acquired a new stake in ResMed during the third quarter worth about $26,000. Capital Advisors Ltd. LLC raised its stake in ResMed by 2,000.0% during the second quarter. Capital Advisors Ltd. LLC now owns 147 shares of the medical equipment provider’s stock worth $31,000 after acquiring an additional 140 shares during the period. Ronald Blue Trust Inc. raised its stake in ResMed by 72.8% during the fourth quarter. Ronald Blue Trust Inc. now owns 159 shares of the medical equipment provider’s stock worth $35,000 after acquiring an additional 67 shares during the period. Guardian Wealth Advisors LLC acquired a new stake in ResMed during the third quarter worth about $36,000. Finally, Coston McIsaac & Partners acquired a new stake in ResMed during the second quarter worth about $41,000. Institutional investors and hedge funds own 64.73% of the company’s stock.

ResMed Company Profile

(Get Rating)

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.